STAT3 and intrahepatic cholangiocarcinoma: When STATTIC was used, the inhibitor of STAT3 and PD98059, an inhibitor of the ERK pathway, was used to treat cells and inhibit the activation of STAT3 and ERK, the protective effect of BAB on ICC was also abolished, and the reduction of p-STAT3 expression was observed, while PD98059 inhibited ERK phosphorylation.